Indeed, our results show that minimal peptide epitopes are extremely potent at inducing CTL killing and amplifying CD8+ T cells both in the tumor and in the circulation, yet they do not boost preexisting antibody responses, likely due to their low molecular weight. The gene discussed is CD8A; the disease is neoplasm.